학술논문
Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
16000641